Janis Naeve
Directeur/Membre du Conseil chez Ren Pharmaceuticals, Inc.
Profil
Janis Naeve joined Cota in 2022 as a Partner on the investment team.
Prior to Cota, Janis was at Amgen, Inc. since 2005 where she was instrumental in establishing the corporate venture group, Amgen Ventures.
During that time she led a team that invested in innovative companies developing drug discovery platforms and therapeutics.
More recently Amgen Ventures’ investment portfolio also encompassed companies in digital health, healthcare IT, and advanced data analytics such as AI and machine learning.
Janis served on the Caltech Accelerator Fund Committee, the Silicon Valley Bank Healthcare Advisory Committee, the KidneyX Accelerator, and the Advisory Council of Incubator Coalition.
Janis was named 2021’s Fiercest Women in Life Sciences by Fierce Pharma.
Janis has an undergraduate degree in Microbiology from Cal Poly Pomona, a Ph.D.
in Experimental Pathology from University of Southern California, and completed a post-doctoral fellowship in Neurobiology at Caltech.
Postes actifs de Janis Naeve
| Sociétés | Poste | Début |
|---|---|---|
Ren Pharmaceuticals, Inc.
 Ren Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ren Pharmaceuticals was formed in the fall of 2006 with the aim of bringing together talented and experienced people who are passionate about building a cardio-renal/renal- focused drug development company. Ren Pharmaceuticals closed a Series A financing in November 2006 with Sanderling Ventures, Venrock Associates and Amgen Ventures as investors. The company's R&D is currently located in South San Francisco, California. | Directeur/Membre du Conseil | - |
California Institute of Technology
 California Institute of Technology Other Consumer ServicesConsumer Services California Institute of Technology provides education focusing on science, engineering, academia, business, and public service. The company was founded in 1891 and it is headquartered in Pasadena, CA. | Corporate Officer/Principal | - |
Probius DX, Inc.
 Probius DX, Inc. Medical SpecialtiesHealth Technology ProbiusDx, Inc. develops devices that analyses multiple target proteins. The company was founded by Roger T. Howe, Chaitanya Gupta and Emmanuel P. Quevy and is headquartered in El Cerrito, CA. | Directeur/Membre du Conseil | 19/10/2022 |
Cota Capital Management LLC
 Cota Capital Management LLC Investment ManagersFinance Cota Capital Management LLC (Cota Capital) is a venture capital firm founded in 2014 by Babak Poushanchi and Bobby Yazdani. The firm is headquartered in San Francisco, California. | Private Equity Investor | 01/05/2022 |
Anciens postes connus de Janis Naeve
| Sociétés | Poste | Fin |
|---|---|---|
| Incubate Coalition | Consultant / Advisor | 01/04/2022 |
| ALECTOR, INC. | Corporate Officer/Principal | - |
Amgen Ventures LLC
 Amgen Ventures LLC Investment ManagersFinance Amgen Ventures LLC (Amgen Ventures) is a venture capital subsidiary of Amgen, Inc. founded in 2004. The firm is headquartered in Thousand Oaks, California. | Private Equity Investor | - |
| NEXIMMUNE, INC. | Directeur/Membre du Conseil | - |
| SURFACE ONCOLOGY, INC. | Directeur/Membre du Conseil | - |
Formation de Janis Naeve
| University of Southern California | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| NEXIMMUNE, INC. | Health Technology |
| ALECTOR, INC. | Health Technology |
| Entreprise privées | 13 |
|---|---|
Ren Pharmaceuticals, Inc.
Ren Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ren Pharmaceuticals was formed in the fall of 2006 with the aim of bringing together talented and experienced people who are passionate about building a cardio-renal/renal- focused drug development company. Ren Pharmaceuticals closed a Series A financing in November 2006 with Sanderling Ventures, Venrock Associates and Amgen Ventures as investors. The company's R&D is currently located in South San Francisco, California. | Health Technology |
X-Ceptor Therapeutics, Inc.
 X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
Aurora Biosciences Corp.
 Aurora Biosciences Corp. BiotechnologyHealth Technology Aurora Biosciences Corp. designs and develops proprietary drug discovery systems, services and technologies to the discovery of new medicine. It develops a proprietary ultra-high throughput screening platform that uniquely integrates innovative fluorescence chemistry, molecular biology, miniaturization, automation, and informatics. The company also provides assay development and screening services. Aurora was founded in 1995 and is located in San Diego, CA. | Health Technology |
Accelerator Services Corp
 Accelerator Services Corp Investment ManagersFinance Accelerator Services Corp (Accelerator Services) is a venture capital firm founded in 2003 by Carl Weissman and Rodney F. Burgar. The firm is headquartered in Seattle, Washington. | Finance |
Oncofactor Corp.
 Oncofactor Corp. Pharmaceuticals: MajorHealth Technology Oncofactor Corp. develops antibody drugs against new biologic targets in cancer. Its cancer therapeutics that disrupt signaling pathways between tumors and the immune system. The company was founded by Sarah Ellen Warren in 2011 and is headquartered in Seattle, WA. | Health Technology |
Groove Biopharma Corp.
 Groove Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Groove Biopharma Corp. focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) were involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma's core technology addressed a new avenue of nucleotide therapeutic drug discovery via modulation of cellular mirna. Used exclusive technology, Groove Biopharma were generated a series of lead candidates with the potential to be best-in-class therapeutics. By incorporated proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presented promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.The company was founded in 2008 and is headquartered in Seattle,UN. | Commercial Services |
Acylin Therapeutics, Inc.
 Acylin Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Acylin Therapeutics, Inc. develops drugs for cancer. The company was founded by Philip A. Cole, Peter S. DiStefano, Ronen Marmorstein, Suresh K. Jain and Roydon Price in 2009 and is headquartered in Seattle, WA. | Health Technology |
DecImmune Therapeutics, Inc.
 DecImmune Therapeutics, Inc. BiotechnologyHealth Technology DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute and tissue damaging inflammation. It engages in developing an antibody-based therapeutic that can prevent tissue damage and preserve organ function by inhibiting activation of the N2 neoepitope in the innate autoimmune pathway. The company was founded by Michael Carroll, Richard S. Foemmel, and Francis Moore Jr. on March 27, 2001 and is headquartered in Cambridge, MA.^ | Health Technology |
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Amgen Ventures LLC
Amgen Ventures LLC Investment ManagersFinance Amgen Ventures LLC (Amgen Ventures) is a venture capital subsidiary of Amgen, Inc. founded in 2004. The firm is headquartered in Thousand Oaks, California. | Finance |
Probius DX, Inc.
Probius DX, Inc. Medical SpecialtiesHealth Technology ProbiusDx, Inc. develops devices that analyses multiple target proteins. The company was founded by Roger T. Howe, Chaitanya Gupta and Emmanuel P. Quevy and is headquartered in El Cerrito, CA. | Health Technology |
| Incubate Coalition | |
Cota Capital Management LLC
Cota Capital Management LLC Investment ManagersFinance Cota Capital Management LLC (Cota Capital) is a venture capital firm founded in 2014 by Babak Poushanchi and Bobby Yazdani. The firm is headquartered in San Francisco, California. | Finance |